Return to homepagePandemic Pact

A randomized phase 2 placebo-controlled clinical study named ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) to test the impact of an AT2R agonist (VP01) on progression of COVID-19 disease

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    University College London and Vicore Pharma

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 2 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Vicore Pharma, with funding from LifeArc, is set to commence Phase 2 clinical trials testing an already available drug candidate in 100 hospitalised COVID-19 patients. Researchers at Vicore Pharma, in collaboration with University College London, have identified that one of their candidate drugs VP01 (Compound 21; C21), currently also in development for pulmonary fibrosis, could reduce the severity of COVID-19 disease. It has the potential to reduce Acute Respiratory Distress Syndrome also known as severely inflamed lungs which is commonly the cause of death in severe cases of COVID-19